Print

HVTN 042 / ANRS VAC 19

A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants

Trial Details:

I/II Completed
National Institute of Allergy and Infectious Diseases (NIAID), French National Agency for Research on AIDS and viral hepatitis (ANRS) , HIV Vaccine Trials Network (HVTN) May 01, 2004
ALVAC vCP1452,LIPO-5 Canarypox gp120, TM gp41, gag, protease, nef, pol MN/LAI; 5 lipopeptides containing CTL epitopes from the Gag, Nef, and Pol B
ALVAC vCP1452 Viral Vector - Pox
LIPO-5 Protein
USA 174
NCT00076063
http://clinicaltrials.gov/show/NCT00076063